IHH Healthcare Bhd.

MIDDLETON, Wis., Sept. 29. 2025 /PRNewswire/ -- Leo Cancer Care today confirmed an expansion of its collaboration with IHH Healthcare to bring upright radiotherapy solutions to its hospital network. Building on IHH's 2024 entry into the Upright Photon Alliance, the group is looking to introduce Leo Cancer Care's newly launched upright linear accelerators (linacs), Grace™, across its hospitals to provide the potential benefits of upright photon therapy to its patients. Following the initial partnership with Leo Cancer Care, IHH has also become an equity investor in Leo Cancer Care, further demonstrating its commitment to advancing the technology and reflecting its belief in the long-term benefits of the upright solutions. IHH is now extending the collaboration into the proton therapy space, pursuing the potential of Leo Cancer Care's compact Marie® upright proton solution to make this advanced treatment more accessible and cost-effective. This expanded partnership reflects IHH's aspiration to deliver Care. For Good. through meaningful innovation to catalyse next-level care for patients and the community. Proton therapy has long been recognised for its precision in targeting tumours, but adoption has been limited by the size, cost, and infrastructure demands of conventional systems. By rotating the patient rather than the beam, Leo Cancer Care's upright approach dramatically reduces system size and cost, creating a future where proton therapy is within reach for more patients. Through this expansion, IHH is leading the way in Asia by moving towards both upright photon and proton therapy solutions. Elizabeth Han, Group Head of Innovation and Transformation at IHH Healthcare, said: "At IHH, we see technology and innovation as powerful enablers of better patient outcomes and experience. Through the Upright Photon Alliance, we are reshaping cancer care and the future of radiation therapy." Stephen Towe, Chief Executive Officer of Leo Cancer Care, commented: "IHH's interest in Upright Radiotherapy reflects the promise of our simplified and innovative approach. Instead of making radiotherapy more complicated and expensive, we are addressing the evolving healthcare needs of tomorrow." Please note: The Leo Cancer Care Grace solution is not yet commercially available and is presented for research purposes only. About IHH Healthcare IHH Healthcare is a leading multinational healthcare provider shaping the future of care. Driven by our aspiration to Care. For Good., we unite medical excellence and innovation, pushing boundaries through our trusted brands such as Acibadem, Gleneagles, Fortis, Island, Mount Elizabeth, Pantai, Parkway and Prince Court. Across 10 countries, including Malaysia, Singapore, Türkiye, India and Greater China, our 70,000-strong team delivers world-class excellence every day, within and beyond our 140 healthcare facilities, including more than 80 hospitals. Our comprehensive services span the full healthcare continuum, from primary and ambulatory to quaternary care, complemented by diagnostics, imaging, rehabilitation, telehealth and home care. In partnership with our stakeholders, IHH is advancing value-based care, building a sustainable healthcare ecosystem and creating meaningful impact, as we work towards our vision to become the world's most trusted healthcare services network. SOURCE Leo Cancer Care WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Korean government launches tariff support for medtech companies The South Korean Ministry of Health and Welfare and the Korea Health Industry Development Institute have launched a tariff support centre to help medical device companies navigate recent trade challenges. The Biohealth Industry Tariff Support Center, established on 25 April, aims to assist companies in the industry, including medical AI developers, in dealing with the impacts of the new tariff measures of their biggest market, the United States, as well as strengthening their long-term trade risk management capabilities. "With the ongoing uncertainty surrounding the trade policy of the US – the world’s largest market for the biohealth sector – Korean pharmaceutical, medical device, and cosmetics exporters are experiencing heightened anxiety and tension. Through the support centre, we will actively engage with companies on the ground and coordinate a whole-of-government effort to minimise damages and deliver a swift, comprehensive response," said Jung Eunyoung, MOHW director-general for Health Industry Policy. Qure.ai to power Johnson & Johnson MedTech's lung cancer screening clinics in India Johnson & Johnson MedTech has teamed up with Qure.ai to launch AI-powered lung cancer screening clinics across hospitals in India. Their strategic partnership will see diagnostic hubs utilise AI to detect incidental pulmonary nodules. Based on a press release, Qure.ai's technology will be deployed across 30 sites. "In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment," noted Anuj Virmani, managing director of Johnson & Johnson MedTech India. Mount Elizabeth Hospital enhances patient experience with AI Private hospital Mount Elizabeth Hospital in Singapore has introduced a new patient web application powered by AI. The new app utilises AI to allow inpatients to request in-room amenities. It also features augmented reality to help them navigate the app. Additionally, a separate finder app was also launched that helps visitors and outpatients find their way around the hospital. These new applications add to initiatives enhancing patient experience in the 300-bed hospital. Last year, Mount Elizabeth Hospital introduced a multi-language television channel.

Malaysia's IHH Healthcare Bhd on Friday said it will acquire the remaining stake in hospital chain operator Ravindranath GE Medical Associates (RGE), held by Ravindranath Kancherla and his affiliates, for around Rs 740 crore. IHH Healthcare has inked the agreement to acquire the stake in RGE through its wholly-owned subsidiary Gleneagles Development. Kancherla is the founder of RGE, which owns the chain of Gleneagles Global Hospitals, a leading tertiary and quaternary healthcare chain. Gleneagles Global Hospitals operates six multi-super-speciality hospitals across Hyderabad, Chennai, Bengaluru, and Mumbai, with a capacity of around 1,500 beds. "This latest investment is a significant milestone in IHH's expansion strategy and long-term goals in India. Backed by unparalleled clinical outcomes, the acquisition strengthens our position in the country," IHH Healthcare India CEO Anurag Yadav said in a statement. The transaction is expected to be completed by the fourth quarter of 2023, it said. With this transaction, IHH will strengthen its leading position as a tertiary and quaternary care platform, including multi-organ transplants, in India and across its key markets, it added. IHH operates various brands like Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway.